You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

The metastasis suppressor KISS1 lacks antimetastatic activity in the C8161.9 xenograft model of melanoma

Navenot, Jean-Marca; Evans, Barrya; Oishi, Shinyab; Setsuda, Shoheib; Fujii, Nobutakab; Peiper, Stephen C.a

Melanoma Research:
doi: 10.1097/CMR.0b013e328350fa07
ORIGINAL ARTICLES: Basic research
Abstract

The objective of this study was to use the established xenograft model of human melanoma (C8161.9) to test a pharmacological approach to the effect of the metastasis suppressor KISS1. A KISS1 analog was used to inhibit the metastatic development of C8161.9 cells in nude mice. Further experiments were performed to test the validity of the C8161.9 model and test the connection between KISS1 expression and loss of metastatic potential. New clones of C8161.9 cells were obtained, with or without KISS1 expression, and were tested for metastasis formation. The absence of benefit in survival with the KISS1 analog compared with PBS prompted us to revisit the C8161.9 model. We found that the cells expressing KISS1, used in the previous study and obtained by transfection and single-cell cloning, were defective for both formation of orthotopic tumors and metastases. In mixing experiments, these cells could not suppress orthotopic tumor growth of KISS1-negative C8161.9 cells, suggesting that the suppression of metastasis by C8161.9-KISS1 cells may be intrinsic to the selected clone rather than related to KISS1 expression. Isolation of clones from parental C8161.9 cells in soft agar yielded cell populations that phenotypically and genotypically mimicked the KISS1-positive clone. In addition, new clones expressing KISS1 did not show any decrease in metastatic growth. These data demonstrate the heterogeneity of cell types in the C8161.9 cell line and the high risk of artifact linked to single-cell selection. A different xenograft model will be necessary to evaluate the use of KISS1 analogs as antimetastatic therapy.

Author Information

aDepartment of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

bGraduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan

Correspondence to Jean-Marc Navenot, PhD, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, Room JAH 336C, Philadelphia, PA 19107, USA Tel: +1215 503 6150; fax: +1215 503 5929; e-mails: jean-marc.navenot@jefferson.edu, navenot.jefferson@gmail.com

Received July 7, 2011

Accepted January 3, 2012

© 2012 Lippincott Williams & Wilkins, Inc.